Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer. (Q52207721)

27 April 2018

title

Hyperfractionated radiotherapy for clinical stage II non-small cell lung cancer. (English)

1 reference

27 April 2018

author name string

Jeremic B

1

1 reference

27 April 2018

Shibamoto Y

2

1 reference

27 April 2018

Acimovic L

3

1 reference

27 April 2018

Milisavljevic S

4

1 reference

27 April 2018

publication date

1 May 1999

1 reference

27 April 2018

Radiotherapy and Oncology

published in

1 reference

27 April 2018

volume

51

1 reference

27 April 2018

issue

2

1 reference

27 April 2018

page(s)

141-145

1 reference

27 April 2018

The Evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Comparison of the Radiation Therapy Oncology Group and American Joint Committee on Cancer staging systems among patients with non-small cell lung cancer receiving hyperfractionated radiation therapy. A report of the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Medically Inoperable Lung Carcinoma: The Role of Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

'Tumour volume' as a predictor of survival after resection of non-small-cell lung cancer (NSCLC)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Absence of thoracic radiation myelitis after hyperfractionated radiation therapy with and without concurrent chemotherapy for Stage III nonsmall-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Survival after resection of stage II non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

A new international staging system for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Clinical stage II non-small cell lung cancer treated with radiation therapy alone. The significance of clinically staged ipsilateral hilar adenopathy (N1 disease)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Curative radiotherapy for technically operable stage I nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Inoperable non-small cell lung cancer: a retrospective analysis of 427 patients treated with high-dose radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

Curative radiotherapy of early operable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2899%2900032-8

7 January 2021

10.1016/S0167-8140(99)00032-8

Identifiers

DOI

1 reference

27 April 2018

1 reference

27 April 2018